A clinical case of the development of therapeutic side effects in an epileptic woman of childbearing age is presented. The development of therapeutic side effects occurred on the background of an intermediate therapeutic dose of a valproic acid formulation and was associated with primary (idiopathic) and secondary (valproate-induced) impairments to the folate cycle on the background of a combination of a polymorphism in the CYP2C9*3 gene and a mutation in the MTHFR gene.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
OMIM *607093, www/ncbi/nlm/nih.gov/entrez/dispomim. cgi?id=607093.
V. S. Baranov, E. V. Baranova, T. E. Ivashchenko, and M. V. Aseev, The Human Genome and ‘Predisposition’ Genes. Introduction to Predictive Medicine [in Russian], Intermedika, St. Petersburg (2000).
Yu. B. Belousov, A. B. Gekht, L. E. Milchakova, et al., “Clinicaleconomic efficacy of the treatment of patients with epilepsy,” in: Qualitative Clinical Practice [in Russian], (2002).
V. A. Karlov, Epilepsy in Children and Adults, Women and Men: Guidelines for Physicians [in Russian], OAO Meditsina Press, Moscow (2010).
V. G. Kukes, D. A. Sychev, and E. V. Shikh, “Studies of the drug biotransformation – a pathway to increasing the efficacy and safety of drug treatment,” Vrach, No. 1, 6–8 (2007).
V. G. Kukes, S. V. Grachev, D. A. Sychev, and G. V. Ramenskaya, Drug Metabolism. The Scientific Grounds for Personalized Medicine: Guidelines for Physicians [in Russian], GEOTAR-Media, Moscow (2008).
M. S. Pilyugina, “Pathways of the metabolism of valproic acid formulations and carbamazapine,” Vestn. Kin. Boln. No. 51, 3, No. 10, 52–55 (2010).
D. A. Sychev, G. V. Ramenskaya, I. V. Ignatiev, and V. G. Kukus, Clinical Pharmacogenetics [in Russian],V. G. Kukes and N. P. Bochkova (eds.), GEOTAR-Media, Moscow (2007).
N. A. Shnaider, M. S. Pilyugina, D. V. Dmitrenko, et al., “A personalized approach to the treatment of epilepsy – a pathway to decreasing cases of drug resistance,” Biomeditsina, No. 3, 172–174 (2010).
N. A. Shnaider, M. S. Pilyugina, D. V. Dmitrenko, et al., “An individual approach to the selection of antiepileptic treatment and the clinical pharmacological monitoring of anticonvulsants – a pathway to rational drug use,” Klin. Farmakol. Ter., No. 6, 178–180 (2010).
N. A. Shnaider, M. S. Pilyugina, D. V. Dmitrenko, et al., “The frequency of adverse drug reactions on the background of use of anticonvulsants in epilepsy patients,” Klin. Farmakol. Ter., No. 6, 180–184 (2010).
M. G. Aspinall and R. G. Hamermesh, “Realizing the promise of personalized medicine,” Harv. Bus. Rev., 85, No. 10, 108–117 (2007).
M. Brooks, “Valproic acid in pregnancy linked to several congenital malformations,” New Engl. J. Med., 362, 2185–2193 (2010).
J. E. Finan and R. Y. Zhao, “From molecular diagnostics to personalized testing,” Pharmacogenomics, 8, No. 1, 85–99 (2007).
E. Giovanucci, J. Chen, S. A. Smith-Warner, et al., “Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas,” Cancer Epidemiol. Biomarkers Prev., 12, No. 10, 970–979 (2003).
R. M. Gueant-Rodriguez, C. Rendeli, B. Namour, et al., “Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans,” Neurosci. Lett., 334, No. 3, 189–192 (2003).
P. N. Kirke, J. L. Mills, A. M. Molloy, et al., “Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study,” Brit. Med. J., 328, No. 7455, 1535–1536 (2004).
L. A. Kluijtmans, L. P. van den Heuvel, and G. H. Boers, “Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene, is a genetic risk factor for cardiovascular disease,” Am. J. Hum. Genet., 58, No. 1, 35–41 (1996).
I. Matok, R. Gorodisher, G. Koren, et al., “Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations,” Brit. J. Clin. Pharmacol., 68, No. 6, 956–962 (2009).
A. Pilotto, D. Seripa, M. Franceschi, et al., “Genetic susceptibility to non-steroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms,” Gastroenterology, 133, No. 2, 465–471 (2007).
D. M. Roberts and N. A. Buckley, “Pharmacokinetic considerations in clinical toxicology: clinical applications,” Clin. Pharmacokinet., 46, No. 11, 897–939 (2007).
S. C. Sim, C. Risinger, M. L. Dahl, et al., “A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants,” Clin. Pharmacol. Ther., 79, No. 1, 103–113 (2006).
G. Toffoli, A. Russo, and F. Innocenti, “Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients,” Int. J. Cancer, 103, No. 3, 194–199 (2003).
T. K. Kiang, P. C. Ho, M. R. Anari, et al., “Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype,” Toxicol. Sci., 94, No. 2, 261–271 (2006).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 111, No. 5, Iss. 2, Epilepsy, pp. 31–37, May, 2011.
Rights and permissions
About this article
Cite this article
Shnaider, N.A., Sychev, D.A., Pilyugina, M.S. et al. Importance of the Pharmacokinetics of Valproic Acid in an Individualized Approach to the Treatment of Epileptic Women of Fertile Age. Neurosci Behav Physi 42, 963–968 (2012). https://doi.org/10.1007/s11055-012-9663-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-012-9663-2